Analyst Price Target is $6.00
▲ +50.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MannKind in the last 3 months. The average price target is $6.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 50.00% upside from the last price of $4.00.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in MannKind. This Buy consensus rating has held steady for over two years.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.